Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

NCT00411645 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

681

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: maribavir
OTHER: placebo

Sponsor

Shire